Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Genetics to Distribute CLS Cell Lines Service Products

NEW YORK (GenomeWeb) – Oxford Genetics said today that it has signed a worldwide distribution agreement with CLS Cell Lines Service to combine CLS's cell lines with Oxford's current menu of bio-therapeutic research products and services.

The agreement gives Oxford's customers access to over 400 mammalian cell lines which can be used in the firm's custom cell line engineering and development services.

Oxford said it will also work to promote CLS's greater product portfolio, making it available to both academic and commercial customers working in basic research and drug discovery.

"This agreement represents a major opportunity for us to meet the needs of our customers and their demand for improved workflows," Oxford Chief Commercial Officer Paul Brooks said in a statement. "CLS’s cell lines are highly complementary to our existing portfolio, which includes the SnapFast range of plasmids and associated technologies for rapid and high-throughput vector construction, and our new services to be launched in Q2 2017 focusing on gene editing and engineering."